Logo

OpiCalc

FavoritesSpecialtiesDrugsGuidelinesMost Used

Quick Access

Favorites
Most Used

All Specialties

OpiCalc Logo
Clinical CalculatorsDrugsGuidelines
SpecsDrugsGuides
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
OpiCalc Logo

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required
Ready for the Bedside

Resources

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of UseCookie Policy

Support

Contact Us

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2026

•

All Rights Reserved

Registry Hub
Potassium Binder/Discontinued

SODIUM POLYSTYRENE SULFONATE

SODIUM POLYSTYRENE SULFONATE

Clinical safety rating

caution

Comprehensive clinical and safety monograph for SODIUM POLYSTYRENE SULFONATE (SODIUM POLYSTYRENE SULFONATE).


What is SODIUM POLYSTYRENE SULFONATE?

Comprehensive clinical and safety monograph for SODIUM POLYSTYRENE SULFONATE (SODIUM POLYSTYRENE SULFONATE).

Indications & Uses

Treatment of hyperkalemia

Compare SODIUM POLYSTYRENE SULFONATE vs KOMZIFTI →View all Potassium Binder drugs →

Mechanism of Action

Sodium polystyrene sulfonate is a cation-exchange resin that exchanges sodium ions for potassium ions in the gastrointestinal tract, primarily in the large intestine, thereby reducing serum potassium levels.

What the body does with it

MetabolismSodium polystyrene sulfonate is not absorbed systemically; it acts locally in the gastrointestinal tract.
ExcretionPrimarily fecal (via gut) as the resin is not absorbed. Only a small fraction (approximately 0.5-1% of the administered dose) is absorbed, and the absorbed portion is eliminated renally as the sulfonate moiety. Renal elimination contributes minimally to total clearance (<1%).
Half-lifeThe terminal elimination half-life of the absorbed fraction is not well-defined due to minimal systemic absorption; hence, half-life is not clinically relevant. The resin itself is not eliminated from the body via metabolism or excretion but is passed in feces.
Protein bindingNegligible (<1%). The resin is not absorbed; therefore, protein binding of the intact resin is not applicable. The absorbed sulfonate moiety has negligible protein binding.
Volume of DistributionNot applicable (Vd essentially 0 for the resin as it remains in the GI tract). For the absorbed fraction, Vd is minimal (<0.1 L/kg) due to rapid renal excretion.
BioavailabilityOral: Essentially 0% absorbed (non-absorbable resin). Rectal: Similarly, systemic absorption is negligible (<0.5%).
Onset of ActionOral: 2-12 hours. Rectal (enema): 2-4 hours. The onset varies based on gut motility and stool transit time.
Duration of ActionOral: Effect lasts up to 4-6 hours after a single dose; repeated doses are needed for sustained potassium lowering. Rectal: Duration is shorter, typically 2-4 hours. Note: The drug exchanges sodium for potassium in the gut lumen, and clinical effect lasts as long as the resin is in contact with gastrointestinal contents.
Molecular Weight1000

Classification & Brands

Dosing & administration

Adults: 15 g orally once daily to four times daily, as a single dose or suspension in water or syrup (3-4 mL per gram of resin). May also be administered rectally as a retention enema: 30-50 g every 6-8 hours, retained for at least 30-60 minutes.

Dosage formSUSPENSION
Renal impairmentNo specific dose adjustment is recommended based on GFR; however, use with caution in patients with renal impairment due to risk of electrolyte abnormalities and colonic necrosis. Alternative potassium-lowering agents are preferred in severe renal disease.
Liver impairmentNo specific Child-Pugh-based dose modifications are established. Use with caution in patients with hepatic impairment due to potential for fluid and electrolyte disturbances.
Pediatric useChildren: 1 g/kg orally per dose, given 1-4 times daily, or rectally as a retention enema: 1 g/kg per dose every 6-8 hours. Adjust based on serum potassium levels and body weight.
Geriatric useElderly patients may be more susceptible to electrolyte imbalances and dehydration. Use the lowest effective dose and monitor serum potassium and sodium closely. Consider alternative therapy if risk of bowel ischemia or constipation is high.

Use during pregnancy

1st trimesterSodium polystyrene sulfonate is not absorbed systemically; therefore, no fetal risk is expected. However, use only if clearly needed due to potential maternal electrolyte disturbances (e.g., hypokalemia) that could affect the fetus.
2nd trimesterSame as trimester 1. No known teratogenicity due to lack of absorption. Monitor maternal potassium levels to avoid hypokalemia.
3rd trimesterSame as trimester 1 and 2. Use with caution near delivery due to potential for maternal electrolyte imbalances that could affect neonatal outcomes.

Clinical note

Comprehensive clinical and safety monograph for SODIUM POLYSTYRENE SULFONATE (SODIUM POLYSTYRENE SULFONATE).

Placental transferNo significant placental transfer due to lack of systemic absorption.
BreastfeedingSodium polystyrene sulfonate is not absorbed from the gastrointestinal tract, so breastfeeding is considered safe. However, monitor maternal electrolytes as hypokalemia could affect milk production and composition.
Lactation RatingL1 - Safe
Teratogenic RiskNo adequate studies in pregnant women. Animal reproduction studies not conducted. Sodium polystyrene sulfonate is not absorbed systemically, so fetal exposure is minimal. However, potential maternal electrolyte disturbances (e.g., hypokalemia) may indirectly affect the fetus. Risk cannot be ruled out; use only if clearly needed.
Fetal MonitoringMonitor serum potassium, calcium, and magnesium levels regularly during therapy. Assess for signs of electrolyte imbalance (e.g., cardiac arrhythmias, muscle weakness). Fetal monitoring not specifically required but maternal stability important.
Fertility EffectsNo known effects on fertility. No human or animal data available.

Warnings & precautions

■ FDA Black Box Warning

No FDA black box warning.

Side Effect Profile

Serious Effects

Absolute Contraindications

Obstructive bowel diseaseNeonates with reduced gut motility (risk of impaction)Hypokalemia (serum potassium < 3.5 mEq/L)HypocalcemiaConcurrent use of sorbitol (risk of intestinal necrosis)

Clinical Precautions

PrecautionsRisk of intestinal necrosis, particularly with concomitant use of sorbitol, Electrolyte disturbances (hypokalemia, hypocalcemia, hypomagnesemia), Sodium overload in patients with heart failure or hypertension, Use with caution in patients with severe constipation or impaction, Potential for aspiration if given orally to patients with impaired gag reflex
Food/DietaryAvoid foods high in potassium (e.g., bananas, oranges, potatoes, spinach, avocados) and high-sodium foods to optimize potassium removal and prevent sodium overload. Do not mix SPS with juices containing potassium (e.g., orange juice). Maintain adequate fluid intake unless fluid-restricted. Avoid laxative use. No specific interaction with alcohol, but excess alcohol can affect electrolyte balance.

Clinical Tips & Counseling

Clinical PearlsSodium polystyrene sulfonate (SPS) exchanges sodium for potassium in the colon. Onset of action is 2-12 hours (oral) or 30-60 minutes (rectal). Monitor for hypokalemia, hypomagnesemia, and sodium overload, especially in patients with renal impairment, heart failure, or hypertension. Do not administer orally in patients with impaired bowel motility (e.g., postoperative ileus, constipation) due to risk of colonic necrosis. Concurrent use with sorbitol increases risk of intestinal necrosis; avoid sorbitol-containing formulations. SPS is less effective than newer potassium binders (patiromer, sodium zirconium cyclosilicate). Rectal administration is preferred when rapid effect needed, but ensure enema is retained for at least 30-60 minutes. Each gram of SPS exchanges approximately 1 mEq of potassium but also delivers 1 mEq of sodium, which can worsen fluid overload.
Patient AdviceTake this medication exactly as prescribed, usually 1 to 4 times daily. · For oral suspension, mix the powder with water or another liquid (not juice) as directed and drink immediately. Do not mix with orange juice or other potassium-containing liquids. · Do not take this medication within 3 hours of any other oral medication to prevent absorption issues. · This medication may cause constipation or stomach upset. Tell your doctor if you have severe constipation, rectal bleeding, or severe stomach pain. · Avoid using laxatives or stool softeners unless directed by your doctor due to increased risk of bowel problems. · This drug exchanges sodium for potassium, so it may increase your sodium levels. Monitor salt intake if you have high blood pressure or heart failure. · Contact your doctor immediately if you experience muscle weakness, irregular heartbeat, or signs of low potassium (e.g., confusion, leg cramps). · Keep this medication out of reach of children and do not use if the powder has changed color or consistency.

SODIUM POLYSTYRENE SULFONATE Interactions

Loading safety data…

This overview is compiled from peer-reviewed clinical sources and FDA labeling. It's here to support — not replace — clinical judgment. Always verify dosing against your institution's current protocols before prescribing.

On this page

Mechanism of ActionDosing & administrationUse during pregnancyWarnings & precautionsDrug interactions

Compare with

KOMZIFTILOKELMASODIUM ZIRCONIUM CYCLOSILICATESPSVELTASSA

External sources

DailyMed (NIH) PubMed OpenFDA